Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 19/20 | 1.00 |
| ▸ | ESR1 | P03372 | 18/20 | 1.00 |
| ▸ | ESRRA | P11474 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128716 | 0.85 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL5122053 | 0.84 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL5121904 | 0.84 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL14176457 | 0.84 | ESR1 (1.00) | ESR2ESR1ESRRA | |
| SCHEMBL5121607 | 0.83 | ESR2 (0.97) | ESR2ESR1 | |
| SCHEMBL5121612 | 0.83 | ESR2 (0.97) | ESR2ESR1 | |
| SCHEMBL5120796 | 0.80 | ESR2 (0.75) | ESR2ESR1 | |
| SCHEMBL14176452 | 0.79 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL3058875 | 0.76 | ESR1 (0.61) | ESR2ESR1ESRRA | |
| SCHEMBL5127458 | 0.73 | ESR2 (1.00) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | ESR2, ESRRA, ESRRG | ESR2 1/4885ESR1 9/4885ESRRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.